CellInfinity Bio offers an in‑vivo cell therapy platform that programs a patient’s own immune cells to target solid tumors, removing the need for ex‑vivo CAR‑T manufacturing and lymphodepletion. The platform uses directed evolution to create optimized scFv binders, viral vectors, and CAR architectures, plus genomic enhancements that improve T‑cell stemness, persistence, and tumor infiltration. It is aimed at biopharma and clinical researchers seeking scalable, cost‑effective immunotherapies for solid‑tumor indications.
Funding
$13.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current autologous CAR‑T therapies for solid tumors require complex ex vivo manufacturing, lymphodepletion conditioning, and often fail to achieve sufficient tumor infiltration and persistence due to the immunosuppressive tumor microenvironment.
Solution
CellInfinity Bio develops an in vivo cell therapy platform that programs a patient’s own immune cells directly within the body, eliminating the need for costly ex vivo cell expansion and lymphodepletion. The platform applies directed evolution to generate optimized scFv binders, viral vectors, and CAR architectures that enhance delivery, safety, and specificity for solid‑tumor targets. By integrating genomic enhancements, the engineered T cells gain increased stemness, resistance to exhaustion, and improved tumor penetration. The approach aims to produce a self‑sustaining, potent anti‑tumor response while simplifying manufacturing and reducing overall treatment cost.
Target Audience
Primary customers are biopharmaceutical companies and clinical research organizations developing cell‑based immunotherapies for solid tumors, as well as oncology centers seeking scalable, cost‑effective treatment options.
Features
- Evolution‑driven discovery of novel scFv binders targeting solid‑tumor antigens
- Engineered viral vectors optimized for efficient in vivo delivery and tumor specificity
- Modular CAR designs refined through iterative evolution to boost T‑cell activation and persistence
- Genomic augmentation strategies that confer resistance to immunosuppressive microenvironments and enhance stem‑like properties
- Fully in vivo manufacturing workflow that bypasses ex vivo cell expansion and lymphodepletion regimens